Safety and efficacy of anti-programmed cell death-1 monoclonal antibodies before and after allogeneic hematopoietic cell transplantation for relapsed or refractory Hodgkin lymphoma: a multicenter retrospective study
Abstract We conducted a multicenter study on anti-programmed cell death-1 monoclonal antibodies (anti-PD-1 mAbs) before/after allogeneic hematopoietic cell transplantation (allo-HCT) for Hodgkin lymphoma. Anti-PD-1 mAbs were administered to 25 patients before allo-HCT and to 20 after allo-HCT. In pre-allo-HCT setting, the median interval from the last administration to allo-HCT was 59 days. After allo-HCT, 12 patients developed non-infectious febrile syndrome requiring high-dose corticosteroid. The cumulative incidences of grade II–IV acute graft-versus-host disease (aGvHD) were 47.1%. Eight patients who had GvHD prophylaxis with post-transplant cyclophosphamide (PTCy) had less frequent aGvHD (grade II–IV, 14.6% versus 58.8%; P = 0.086). The 1 year overall survival (OS), relapse/progression, and non-relapse mortality rates were 81.3%, 27.9%, and 8.4%. In post-allo-HCT setting, the median interval from allo-HCT to the first administration was 589 days. The overall and complete response rates were 75% and 40%. At 100 days after anti-PD-1 therapy, the cumulative incidences of grade II–IV aGvHD, moderate-to-severe chronic GvHD, and grade 3–4 immune-related toxicity were 15.0%, 30.0%, and 30.0%. While the 1 year relapse/progression rate was 47.4%, the 1 year OS probability was 89.7%. In conclusion, immune-related complications were frequent despite modifications of GvHD prophylaxis or anti-PD-1 mAb dosing. In anti-PD-1-mAb-pretreated patients, PTCy-based GvHD prophylaxis may be effective..
Medienart: |
Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:112 |
---|---|
Enthalten in: |
International journal of hematology - 112(2020), 5 vom: 03. Aug., Seite 674-689 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Ito, Ayumu [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
Themen: |
Allogeneic hematopoietic cell transplantation |
---|
Anmerkungen: |
© Japanese Society of Hematology 2020 |
---|
doi: |
10.1007/s12185-020-02960-4 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
OLC2120134901 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | OLC2120134901 | ||
003 | DE-627 | ||
005 | 20230504174244.0 | ||
007 | tu | ||
008 | 230504s2020 xx ||||| 00| ||eng c | ||
024 | 7 | |a 10.1007/s12185-020-02960-4 |2 doi | |
035 | |a (DE-627)OLC2120134901 | ||
035 | |a (DE-He213)s12185-020-02960-4-p | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q VZ |
100 | 1 | |a Ito, Ayumu |e verfasserin |4 aut | |
245 | 1 | 0 | |a Safety and efficacy of anti-programmed cell death-1 monoclonal antibodies before and after allogeneic hematopoietic cell transplantation for relapsed or refractory Hodgkin lymphoma: a multicenter retrospective study |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
338 | |a Band |b nc |2 rdacarrier | ||
500 | |a © Japanese Society of Hematology 2020 | ||
520 | |a Abstract We conducted a multicenter study on anti-programmed cell death-1 monoclonal antibodies (anti-PD-1 mAbs) before/after allogeneic hematopoietic cell transplantation (allo-HCT) for Hodgkin lymphoma. Anti-PD-1 mAbs were administered to 25 patients before allo-HCT and to 20 after allo-HCT. In pre-allo-HCT setting, the median interval from the last administration to allo-HCT was 59 days. After allo-HCT, 12 patients developed non-infectious febrile syndrome requiring high-dose corticosteroid. The cumulative incidences of grade II–IV acute graft-versus-host disease (aGvHD) were 47.1%. Eight patients who had GvHD prophylaxis with post-transplant cyclophosphamide (PTCy) had less frequent aGvHD (grade II–IV, 14.6% versus 58.8%; P = 0.086). The 1 year overall survival (OS), relapse/progression, and non-relapse mortality rates were 81.3%, 27.9%, and 8.4%. In post-allo-HCT setting, the median interval from allo-HCT to the first administration was 589 days. The overall and complete response rates were 75% and 40%. At 100 days after anti-PD-1 therapy, the cumulative incidences of grade II–IV aGvHD, moderate-to-severe chronic GvHD, and grade 3–4 immune-related toxicity were 15.0%, 30.0%, and 30.0%. While the 1 year relapse/progression rate was 47.4%, the 1 year OS probability was 89.7%. In conclusion, immune-related complications were frequent despite modifications of GvHD prophylaxis or anti-PD-1 mAb dosing. In anti-PD-1-mAb-pretreated patients, PTCy-based GvHD prophylaxis may be effective. | ||
650 | 4 | |a Anti-PD-1 monoclonal antibody | |
650 | 4 | |a Immune checkpoint inhibitor | |
650 | 4 | |a Hodgkin lymphoma | |
650 | 4 | |a Allogeneic hematopoietic cell transplantation | |
700 | 1 | |a Kim, Sung-Won |4 aut | |
700 | 1 | |a Matsuoka, Ken-ichi |4 aut | |
700 | 1 | |a Kawakita, Toshiro |4 aut | |
700 | 1 | |a Tanaka, Takashi |4 aut | |
700 | 1 | |a Inamoto, Yoshihiro |4 aut | |
700 | 1 | |a Toubai, Tomomi |4 aut | |
700 | 1 | |a Fujiwara, Shin-ichiro |4 aut | |
700 | 1 | |a Fukaya, Masafumi |4 aut | |
700 | 1 | |a Kondo, Tadakazu |4 aut | |
700 | 1 | |a Sugita, Junichi |4 aut | |
700 | 1 | |a Nara, Miho |4 aut | |
700 | 1 | |a Katsuoka, Yuna |4 aut | |
700 | 1 | |a Imai, Yosuke |4 aut | |
700 | 1 | |a Nakazawa, Hideyuki |4 aut | |
700 | 1 | |a Kawashima, Ichiro |4 aut | |
700 | 1 | |a Sakai, Rika |4 aut | |
700 | 1 | |a Ishii, Arata |4 aut | |
700 | 1 | |a Onizuka, Makoto |4 aut | |
700 | 1 | |a Takemura, Tomonari |4 aut | |
700 | 1 | |a Terakura, Seitaro |4 aut | |
700 | 1 | |a Iida, Hiroatsu |4 aut | |
700 | 1 | |a Nakamae, Mika |4 aut | |
700 | 1 | |a Higuchi, Kohei |4 aut | |
700 | 1 | |a Tamura, Shinobu |4 aut | |
700 | 1 | |a Yoshioka, Satoshi |4 aut | |
700 | 1 | |a Togitani, Kazuto |4 aut | |
700 | 1 | |a Kawano, Noriaki |4 aut | |
700 | 1 | |a Suzuki, Ritsuro |4 aut | |
700 | 1 | |a Suzumiya, Junji |4 aut | |
700 | 1 | |a Izutsu, Koji |4 aut | |
700 | 1 | |a Teshima, Takanori |4 aut | |
700 | 1 | |a Fukuda, Takahiro |4 aut | |
773 | 0 | 8 | |i Enthalten in |t International journal of hematology |d Springer Singapore, 1991 |g 112(2020), 5 vom: 03. Aug., Seite 674-689 |w (DE-627)170577996 |w (DE-600)1076875-0 |w (DE-576)105258091 |x 0925-5710 |7 nnns |
773 | 1 | 8 | |g volume:112 |g year:2020 |g number:5 |g day:03 |g month:08 |g pages:674-689 |
856 | 4 | 1 | |u https://doi.org/10.1007/s12185-020-02960-4 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_OLC | ||
951 | |a AR | ||
952 | |d 112 |j 2020 |e 5 |b 03 |c 08 |h 674-689 |